Updates are available Correction dated 2025-01-30
Click to view Correction: https://doi.org/10.1038/s41591-025-03540-x
-
Authors
An, Meirui https://orcid.org/0000-0002-4006-8670
Davis, Jessie R.
Levy, Jonathan M. https://orcid.org/0000-0002-8061-7953
Serack, Fiona E. https://orcid.org/0000-0001-7377-219X
Harvey, John W. https://orcid.org/0009-0003-4593-0965
Brauer, Pamela P.
Pirtle, Catherine P. https://orcid.org/0009-0008-4531-5328
Berríos, Kiara N.
Newby, Gregory A.
Yeh, Wei-Hsi https://orcid.org/0000-0001-7507-8177
Kamath, Nikita https://orcid.org/0009-0008-4150-8675
Mortberg, Meredith
Lian, Yuan https://orcid.org/0009-0001-9565-2292
Howard, Michael
DeSouza-Lenz, Kendrick
Guzman, Kenia
Thai, Aaron
Graffam, Samantha
Laversenne, Vanessa
Coffey, Alissa A. https://orcid.org/0000-0003-2335-7793
Frei, Jeannine
Pierce, Sarah E.
Safar, Jiri G.
Deverman, Benjamin E.
Minikel, Eric Vallabh https://orcid.org/0000-0003-2206-1608
Vallabh, Sonia M. https://orcid.org/0000-0003-3824-2702
Liu, David R. https://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (Liu)
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 12 December 2024
First Online: 14 January 2025
Change Date: 30 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03540-x
Competing interests
: M.A., J.R.D., E.V.M., S.M.V. and D.R.L. are inventors on United States patent applications 63/700,235 and 63/718,534 relating to base editing for prion disease. D.R.L. is a consultant and/or equity owner of Prime Medicine, Beam Therapeutics, Pairwise Plants, Exo Therapeutics, Nvelop Therapeutics and Chroma Medicine, some of which are companies that use or deliver genome editing or epigenome-modulating agents. J.R.D., J.M.L. and W.-H.Y. are current employees of Prime Medicine. S.M.V. acknowledges speaking fees from Abbvie, Biogen, Eli Lilly, Illumina and Ultragenyx; consulting fees from Alnylam and Invitae; and research support from Eli Lilly, Gate Bio, Ionis and Sangamo. E.V.M. acknowledges speaking fees from Abbvie, Eli Lilly and Vertex; consulting fees from Alnylam and Deerfield; and research support from Eli Lilly, Gate Bio, Ionis and Sangamo. B.E.D. declares outside interest in Apertura Gene Therapy and Tevard Biosciences and is an inventor on US patent application US11499165B2 relating to the PHP.eB AAV capsid. All other authors declare no competing interests.
